EMOTIONAL/
PSYCHOLOGICAL EFFECTS

Thyroid Eye Disease (TED) is associated with significant psychological and emotional effects1

  • Mild symptoms of TED are often misdiagnosed and can lead to significant delays in treatment of TED2
  • Symptoms of TED extend beyond functional issues, and the psychosocial impact associated with the disease can affect many aspects of patient well-being2,3
  • TED can negatively impact employment, relationships, and self-confidence, frequently leading patients to withdraw from social interaction3,4

Thyroid Eye Disease can cause severe emotional or psychological effects for the patient

63%

OF PATIENTS WITH TED EXPERIENCE PSYCHOSOCIAL DISTRESS DUE TO TED*5

52%

OF PATIENTS WITH TED EXPERIENCE A LOSS OF SELF-CONFIDENCE DUE TO CHANGES IN APPEARANCE†6

42%

OF PATIENTS WITH TED EXPERIENCE ANXIETY AND/OR DEPRESSION‡7

*Based on a modified Graves’ Ophthalmopathy Quality of Life (GO-QOL) survey completed by 128 patients with TED.5

Based on the responses of 250 patients with TED on a questionnaire about their quality of life, occupational disability, and use of psychotherapy.6

Based on an online quality of life assessment survey of 100 patients with inactive or chronic TED.7

Signs and symptoms of TED may not always be visible, so it’s important to ask your patients if they are experiencing any new or worsening TED manifestations8,9

LOCATE A TED SPECIALIST NOW

  1. Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT. Psychosocial morbidity of Graves’ orbitopathy. Clin Endocrinol (Oxf). 2005;63(4):395-402. doi:10.1111/j.1365-2265.2005.02352
  2. Estcourt S, Hickey J, Perros P, Dayan C, Vaidya B. The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. Eur J Endocrinol. 2009;161(3):483-487. doi:10.1530/EJE-09-0383
  3. Ozzello DJ, Kikkawa DO, Korn BS. Early experience with teprotumumab for chronic thyroid eye disease. Am J Ophthalmol Case Rep. 2020;19:100744. doi:10.1016/j.ajoc.2020.100744
  4. Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol. 2002;146(6):751-757. doi:10.1530/eje.0.1460751
  5. Park JJ, Sullivan TJ, Mortimer RH, Wagenaar M, Perry-Keene DA. Assessing quality of life in Australian patients with Graves’ ophthalmopathy. Br J Ophthalmol. 2004;88(1):75-78. doi:10.1136/bjo.88.1.75
  6. Ponto KA, Pitz S, Pfeiffer N, Hommel G, Weber MM, Kahaly GJ. Quality of life and occupational disability in endocrine orbitopathy. Dtsch Arztebl Int. 2009;106(17):283-289. doi:10.3238/arztebl.2009.0283
  7. Cockerham K, Stuertz N, Padnick-Silver L. Quality of life assessment of chronic Thyroid Eye Disease (TED) patients in the United States. Paper presented at: North American Neuro-Ophthalmology Society (NANOS) 47th Annual Meeting; February 20-23, 2021.
  8. Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015:249125. doi:10.1155/2015/249125
  9. Bothun ED, Scheurer RA, Harrison AR, Lee MS. Update on thyroid eye disease and management. Clin Ophthalmol. 2009;3:543-551. doi:10.2147/opth.s5228